Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease - PubMed (original) (raw)

Review

. 2012 Aug 19;57(1):41-7.

doi: 10.1016/j.vph.2012.02.005. Epub 2012 Feb 17.

Affiliations

• PMID: 22366375
• DOI: 10.1016/j.vph.2012.02.005

Review

Relevance of new drug discovery to reduce NF-κB activation in cardiovascular disease

Rosalinda Madonna et al. Vascul Pharmacol. 2012.

Abstract

The transcription factor nuclear factor-κB (NF-κB) is a main regulator of the expression of several genes involved in the activation of inflammation, cell proliferation, cell immunity and apoptosis. Excess or inappropriate activation of NF-κB has been observed in human inflammatory diseases, including atherosclerosis. Because of the extensive involvement of NF-κB signaling in human diseases, efforts have been made in developing inhibitors of this pathway. Here we will provide an overview of the biology of NF-κB activation pathways. We will here especially focus on current knowledge of the role of the classical ("canonical") NF-κB activation pathway as a potential therapeutic target for anti-atherosclerotic therapies in clinical applications, and discuss classical and novel therapeutic strategies to reduce its prolonged activation.

Copyright © 2012 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Similar articles

• NF-κB as a potential therapeutic target in microbial diseases.
  Vitiello M, Galdiero M, Finamore E, Galdiero S, Galdiero M. Vitiello M, et al. Mol Biosyst. 2012 Apr;8(4):1108-20. doi: 10.1039/c2mb05335g. Epub 2012 Feb 6. Mol Biosyst. 2012. PMID: 22311336 Review.
• NF-kappaB signaling: pros and cons of altering NF-kappaB as a therapeutic approach.
  Egan LJ, Toruner M. Egan LJ, et al. Ann N Y Acad Sci. 2006 Aug;1072:114-22. doi: 10.1196/annals.1326.009. Ann N Y Acad Sci. 2006. PMID: 17057194 Review.
• Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation.
  Viatour P, Merville MP, Bours V, Chariot A. Viatour P, et al. Trends Biochem Sci. 2005 Jan;30(1):43-52. doi: 10.1016/j.tibs.2004.11.009. Trends Biochem Sci. 2005. PMID: 15653325 Review.
• The nuclear factor-kappaB (NF-kappaB): from a versatile transcription factor to a ubiquitous therapeutic target.
  Yates LL, Górecki DC. Yates LL, et al. Acta Biochim Pol. 2006;53(4):651-62. Epub 2006 Oct 27. Acta Biochim Pol. 2006. PMID: 17068636 Review.
• Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks.
  Uwe S. Uwe S. Biochem Pharmacol. 2008 Apr 15;75(8):1567-79. doi: 10.1016/j.bcp.2007.10.027. Epub 2007 Nov 4. Biochem Pharmacol. 2008. PMID: 18070616 Review.

Cited by

• Tumor necrosis factor-α-mediated suppression of dual-specificity phosphatase 4: crosstalk between NFκB and MAPK regulates endothelial cell survival.
  Kao DD, Oldebeken SR, Rai A, Lubos E, Leopold JA, Loscalzo J, Handy DE. Kao DD, et al. Mol Cell Biochem. 2013 Oct;382(1-2):153-62. doi: 10.1007/s11010-013-1730-7. Epub 2013 Jun 28. Mol Cell Biochem. 2013. PMID: 23812841 Free PMC article.
• A four-compound remedy AGILe protected H9c2 cardiomyocytes against oxygen glucose deprivation via targeting the TNF-α/NF-κB pathway: Implications for the therapy of myocardial infarction.
  Zhang X, Chen Q, Zhao J, Zhao W, Fan N, Wang Y, Chen H, Rong J. Zhang X, et al. Front Pharmacol. 2023 Jan 13;14:1050970. doi: 10.3389/fphar.2023.1050970. eCollection 2023. Front Pharmacol. 2023. PMID: 36713834 Free PMC article.
• CD137 Regulates NFATc1 Expression in Mouse VSMCs through TRAF6/NF-κB p65 Signaling Pathway.
  Yan J, Yin Y, Zhong W, Wang C, Wang Z. Yan J, et al. Mediators Inflamm. 2015;2015:639780. doi: 10.1155/2015/639780. Epub 2015 Oct 27. Mediators Inflamm. 2015. PMID: 26600673 Free PMC article.
• Dietary Oleocanthal Supplementation Prevents Inflammation and Oxidative Stress in Collagen-Induced Arthritis in Mice.
  Montoya T, Sánchez-Hidalgo M, Castejón ML, Rosillo MÁ, González-Benjumea A, Alarcón-de-la-Lastra C. Montoya T, et al. Antioxidants (Basel). 2021 Apr 23;10(5):650. doi: 10.3390/antiox10050650. Antioxidants (Basel). 2021. PMID: 33922438 Free PMC article.
• Isoliquiritigenin Attenuates Atherogenesis in Apolipoprotein E-Deficient Mice.
  Du F, Gesang Q, Cao J, Qian M, Ma L, Wu D, Yu H. Du F, et al. Int J Mol Sci. 2016 Nov 18;17(11):1932. doi: 10.3390/ijms17111932. Int J Mol Sci. 2016. PMID: 27869741 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science